These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 25500058)

  • 1. Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.
    Smith MA; Reynolds CP; Kang MH; Kolb EA; Gorlick R; Carol H; Lock RB; Keir ST; Maris JM; Billups CA; Lyalin D; Kurmasheva RT; Houghton PJ
    Clin Cancer Res; 2015 Feb; 21(4):819-32. PubMed ID: 25500058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.
    Lok BH; Gardner EE; Schneeberger VE; Ni A; Desmeules P; Rekhtman N; de Stanchina E; Teicher BA; Riaz N; Powell SN; Poirier JT; Rudin CM
    Clin Cancer Res; 2017 Jan; 23(2):523-535. PubMed ID: 27440269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway.
    Engert F; Schneider C; Weiβ LM; Probst M; Fulda S
    Mol Cancer Ther; 2015 Dec; 14(12):2818-30. PubMed ID: 26438158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.
    Daniel RA; Rozanska AL; Thomas HD; Mulligan EA; Drew Y; Castelbuono DJ; Hostomsky Z; Plummer ER; Boddy AV; Tweddle DA; Curtin NJ; Clifford SC
    Clin Cancer Res; 2009 Feb; 15(4):1241-9. PubMed ID: 19174487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411).
    Schafer ES; Rau RE; Berg SL; Liu X; Minard CG; Bishop AJR; Romero JC; Hicks MJ; Nelson MD; Voss S; Reid JM; Fox E; Weigel BJ; Blaney SM
    Pediatr Blood Cancer; 2020 Feb; 67(2):e28073. PubMed ID: 31724813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors.
    Norris RE; Adamson PC; Nguyen VT; Fox E
    Pediatr Blood Cancer; 2014 Jan; 61(1):145-50. PubMed ID: 24038812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does PARP Inhibition Sensitize Chondrosarcoma Cell Lines to Chemotherapy or Radiotherapy? Results From a Three-dimensional Spheroid Cell Model.
    Palubeckaitė I; Venneker S; van den Akker BEWM; Briaire-de Bruijn IH; Boveé JVMG
    Clin Orthop Relat Res; 2023 Mar; 481(3):608-619. PubMed ID: 36729612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma.
    Kizilbash SH; Gupta SK; Chang K; Kawashima R; Parrish KE; Carlson BL; Bakken KK; Mladek AC; Schroeder MA; Decker PA; Kitange GJ; Shen Y; Feng Y; Protter AA; Elmquist WF; Sarkaria JN
    Mol Cancer Ther; 2017 Dec; 16(12):2735-2746. PubMed ID: 28947502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma.
    Gill SJ; Travers J; Pshenichnaya I; Kogera FA; Barthorpe S; Mironenko T; Richardson L; Benes CH; Stratton MR; McDermott U; Jackson SP; Garnett MJ
    PLoS One; 2015; 10(10):e0140988. PubMed ID: 26505995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies.
    Federico SM; Pappo AS; Sahr N; Sykes A; Campagne O; Stewart CF; Clay MR; Bahrami A; McCarville MB; Kaste SC; Santana VM; Helmig S; Gartrell J; Shelat A; Brennan RC; Hawkins D; Godwin K; Bishop MW; Furman WL; Stewart E
    Eur J Cancer; 2020 Sep; 137():204-213. PubMed ID: 32795876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin.
    Ordóñez JL; Amaral AT; Carcaboso AM; Herrero-Martín D; del Carmen García-Macías M; Sevillano V; Alonso D; Pascual-Pasto G; San-Segundo L; Vila-Ubach M; Rodrigues T; Fraile S; Teodosio C; Mayo-Iscar A; Aracil M; Galmarini CM; Tirado OM; Mora J; de Álava E
    Oncotarget; 2015 Aug; 6(22):18875-90. PubMed ID: 26056084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.
    Smith MA; Hampton OA; Reynolds CP; Kang MH; Maris JM; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Wu J; Kurmasheva RT; Wheeler DA; Houghton PJ
    Pediatr Blood Cancer; 2015 Jan; 62(1):91-8. PubMed ID: 25263539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.
    Calabrese CR; Almassy R; Barton S; Batey MA; Calvert AH; Canan-Koch S; Durkacz BW; Hostomsky Z; Kumpf RA; Kyle S; Li J; Maegley K; Newell DR; Notarianni E; Stratford IJ; Skalitzky D; Thomas HD; Wang LZ; Webber SE; Williams KJ; Curtin NJ
    J Natl Cancer Inst; 2004 Jan; 96(1):56-67. PubMed ID: 14709739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling.
    McGonigle S; Chen Z; Wu J; Chang P; Kolber-Simonds D; Ackermann K; Twine NC; Shie JL; Miu JT; Huang KC; Moniz GA; Nomoto K
    Oncotarget; 2015 Dec; 6(38):41307-23. PubMed ID: 26513298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.
    Murai J; Zhang Y; Morris J; Ji J; Takeda S; Doroshow JH; Pommier Y
    J Pharmacol Exp Ther; 2014 Jun; 349(3):408-16. PubMed ID: 24650937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma.
    Heske CM; Davis MI; Baumgart JT; Wilson K; Gormally MV; Chen L; Zhang X; Ceribelli M; Duveau DY; Guha R; Ferrer M; Arnaldez FI; Ji J; Tran HL; Zhang Y; Mendoza A; Helman LJ; Thomas CJ
    Clin Cancer Res; 2017 Dec; 23(23):7301-7311. PubMed ID: 28899971
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeting the DNA repair pathway in Ewing sarcoma.
    Stewart E; Goshorn R; Bradley C; Griffiths LM; Benavente C; Twarog NR; Miller GM; Caufield W; Freeman BB; Bahrami A; Pappo A; Wu J; Loh A; Karlström Å; Calabrese C; Gordon B; Tsurkan L; Hatfield MJ; Potter PM; Snyder SE; Thiagarajan S; Shirinifard A; Sablauer A; Shelat AA; Dyer MA
    Cell Rep; 2014 Nov; 9(3):829-41. PubMed ID: 25437539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma.
    Chugh R; Ballman KV; Helman LJ; Patel S; Whelan JS; Widemann B; Lu Y; Hawkins DS; Mascarenhas L; Glod JW; Ji J; Zhang Y; Reinke D; Strauss SJ
    Cancer; 2021 Apr; 127(8):1301-1310. PubMed ID: 33289920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics.
    Engert F; Kovac M; Baumhoer D; Nathrath M; Fulda S
    Oncotarget; 2017 Jul; 8(30):48794-48806. PubMed ID: 27447864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia.
    Gojo I; Beumer JH; Pratz KW; McDevitt MA; Baer MR; Blackford AL; Smith BD; Gore SD; Carraway HE; Showel MM; Levis MJ; Dezern AE; Gladstone DE; Ji JJ; Wang L; Kinders RJ; Pouquet M; Ali-Walbi I; Rudek MA; Poh W; Herman JG; Karnitz LM; Kaufmann SH; Chen A; Karp JE
    Clin Cancer Res; 2017 Feb; 23(3):697-706. PubMed ID: 27503200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.